THE SUSTAINABLE HEALTHCARE COMPANY
DEAD

Serial Number

90860922

Owner

Patel & Gong, Inc.

Attorney

Francis G. Gleason, Jr.

Filing Date

Aug 2, 2021

Add to watchlist:

No watchlists yet
View on USPTO

THE SUSTAINABLE HEALTHCARE COMPANY Trademark

Serial Number: 90860922

THE SUSTAINABLE HEALTHCARE COMPANY is a trademark filed by Patel & Gong, Inc. on August 2, 2021. The trademark is classified under Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

Patel & Gong, Inc. (7 trademarks)

Washington, DC 20001

Entity Type: 03

Trademark Details

Filing Date

August 2, 2021

Registration Date

Not Registered

Goods & Services

Providing a website featuring blogs and non-downloadable publications in the nature of magazines, brochures, and articles in the field(s) of pharmaceuticals, medicine, healthcare, disease management, nutrition, diet, fitness, and personal health

Downloadable mobile applications for use in obtaining prescription and over the counter medications and referrals to healthcare providers; Downloadable mobile applications for featuring pricing information for prescription drugs and over the counter medications, for purchasing of prescription drugs and over the counter medications, and for providing information regarding health, prescription drugs and over the counter medications; Downloadable software in the nature of a mobile application for use in connection with the collection, analysis, and sharing of personal medical data

Analgesic and muscle relaxant pharmaceutical preparations; Pharmaceutical anti-allergic preparations and substances; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for skin care; Pharmaceutical preparations for skin wounds; Pharmaceutical preparations for treating allergic rhinitis and asthma; Pharmaceutical preparations for treating allergies; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for treating sunburn; Pharmaceutical preparations for treating and preventing tendon and muscle injuries and disorders, sports related injuries, and for knee cartilage regeneration; Pharmaceutical preparations for use in dermatology; Pharmaceutical preparations for use in urology; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of heart rhythm disorders; Pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of kidney diseases; Pharmaceutical preparations for the treatment of musculo-skeletal disorders; Pharmaceutical preparations, namely, anticoagulants; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical preparations, namely, antivirals; Pharmaceutical preparations, namely, appetite suppressants; Pharmaceutical preparations, namely, injectable contraceptives; Pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical products and preparations against dry skin caused by pregnancy; Pharmaceutical products and preparations for hydrating the skin during pregnancy; Pharmaceutical products and preparations for preventing skin blemishes during pregnancy; Pharmaceutical products and preparations to prevent swelling in the legs

Retail pharmacy services; Retail store services for pharmaceutical, veterinary and sanitary preparations and medical supplies; Wholesale store services for pharmaceutical, veterinary and sanitary preparations and medical supplies

Hygienic and beauty care; Medical services; Providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; Providing a web site featuring information in the field of mental health and physical health, including living a healthy and disease free life; Provision of health care and medical services by health care professionals via the Internet or telecommunication networks

Providing temporary use of on-line non-downloadable software and applications for use in obtaining prescription and over the counter medications and referrals to healthcare providers

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Jun 24, 2024 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Jun 24, 2024 ABN2
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Feb 27, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Feb 27, 2024 XELR
NOTIFICATION OF FINAL REFUSAL EMAILED
Nov 27, 2023 GNFN
FINAL REFUSAL E-MAILED
Nov 27, 2023 GNFR
FINAL REFUSAL WRITTEN
Nov 27, 2023 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 7, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 7, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 5, 2023 TROA
NOTICE OF REVIVAL - E-MAILED
Nov 5, 2023 NREV
NOTICE OF REVIVAL - E-MAILED
Nov 5, 2023 NREV
PETITION TO REVIVE-GRANTED
Nov 5, 2023 PETG
TEAS PETITION TO REVIVE RECEIVED
Nov 5, 2023 PROA
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Sep 5, 2023 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Sep 5, 2023 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Sep 5, 2023 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 8, 2023 GNRN
NON-FINAL ACTION E-MAILED
May 8, 2023 GNRT
NON-FINAL ACTION WRITTEN
May 8, 2023 CNRT
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 20, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 20, 2023 CRFA
ASSIGNED TO LIE
Apr 20, 2023 ALIE
NOTICE OF REVIVAL - E-MAILED
Jan 24, 2023 NREV
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 23, 2023 TROA
PETITION TO REVIVE-GRANTED
Jan 23, 2023 PETG
TEAS PETITION TO REVIVE RECEIVED
Jan 23, 2023 PROA
ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Nov 21, 2022 MAB2
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Nov 21, 2022 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Nov 21, 2022 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 6, 2022 GNRN
NON-FINAL ACTION E-MAILED
May 6, 2022 GNRT
NON-FINAL ACTION WRITTEN
May 6, 2022 CNRT
ASSIGNED TO EXAMINER
Apr 29, 2022 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 28, 2021 NWOS
NEW APPLICATION ENTERED
Aug 5, 2021 NWAP